123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A …
DA Colevas, K Misiukiewicz, AT Pearson… - Annals of …, 2021 - annalsofoncology.org
Background Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group
2A (NKG2A), expressed on subsets of Natural Killer (NK) and tumor-infiltrating CD8+ T cells …
2A (NKG2A), expressed on subsets of Natural Killer (NK) and tumor-infiltrating CD8+ T cells …
81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L) 1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck …
J Fayette, J Bauman, S Salas, D Colevas… - Annals of …, 2020 - annalsofoncology.org
Background Monalizumab is an immune checkpoint inhibitor targeting Natural Killer Group
2A (NKG2A) receptor, which is expressed on subsets of Natural Killer (NK) and CD8+ T …
2A (NKG2A) receptor, which is expressed on subsets of Natural Killer (NK) and CD8+ T …
Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head …
J Fayette, G Lefebvre, MR Posner… - Annals of …, 2018 - annalsofoncology.org
Background: Monalizumab (Mona) is an immune checkpoint inhibitor targeting NKG2A
receptors expressed on tumor-infiltrating CD8 T and Natural Killer (NK cells). The NKG2A …
receptors expressed on tumor-infiltrating CD8 T and Natural Killer (NK cells). The NKG2A …
[HTML][HTML] Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with …
RB Cohen, G Lefebvre, MR Posner, JR Bauman… - Annals of …, 2019 - Elsevier
Background Monalizumab is a first in class immune checkpoint inhibitor targeting Natural
Killer Group 2A (NKG2A), which is expressed as a heterodimer with CD94 on subsets of …
Killer Group 2A (NKG2A), which is expressed as a heterodimer with CD94 on subsets of …
935P A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of …
R Galot, C Le Tourneau, LFL Licitra… - Annals of …, 2023 - annalsofoncology.org
Background Monalizumab (mona), a IgG4 Ab targeting the NKG2A receptor, has limited
activity as monotherapy in RM SCCHN. Targeting the NKG2A-HLA-E pathway with PD (L) 1 …
activity as monotherapy in RM SCCHN. Targeting the NKG2A-HLA-E pathway with PD (L) 1 …
[HTML][HTML] A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): results of the I1 cohort of …
R Galot, C Le Tourneau, E Saada-Bouzid, A Daste… - Annals of …, 2019 - Elsevier
Background Patients (pts) with RM SCCHN progressing after platinum have a median
overall survival (OS) of 7-8 months with nivolumab or pembrolizumab. No other drug has …
overall survival (OS) of 7-8 months with nivolumab or pembrolizumab. No other drug has …
[HTML][HTML] A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG …
R Galot, C Le Tourneau, E Saada-Bouzid… - European Journal of …, 2021 - Elsevier
Purpose Monalizumab is a monoclonal antibody targeting the inhibitory natural killer group
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
2A (NKG2A) receptor localised on natural killer (NK) and T cells. Its ligand, the human …
Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD …
6516 Background: Monalizumab is a first-in-class immune checkpoint inhibitor targeting
Natural Killer Group 2A (NKG2A), which is expressed on subsets of Natural Killer (NK), gd T …
Natural Killer Group 2A (NKG2A), which is expressed on subsets of Natural Killer (NK), gd T …
An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck …
AG Sacco, R Chen, D Ghosh, DJL Wong, FP Worden… - 2019 - ascopubs.org
6033 Background: Pembrolizumab (a humanized monoclonal antibody blocking
programmed death receptor-1 [PD-1]), and cetuximab (a chimeric monoclonal antibody …
programmed death receptor-1 [PD-1]), and cetuximab (a chimeric monoclonal antibody …
854O INTERLINK-1: Phase III study of cetuximab (CTX)±monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M …
J Fayette, LFL Licitra, KJ Harrington… - Annals of …, 2023 - annalsofoncology.org
Background First-line (1L) treatment for R/M HNSCC includes ICI+/-CT or CT+ CTX.
Treatment after 1L failure is not clearly defined. Preliminary data suggest M (anti-NKG2A)+ …
Treatment after 1L failure is not clearly defined. Preliminary data suggest M (anti-NKG2A)+ …